COVID-19 Vaccine Study for Liver Cancer Patients on Immunotherapy
Part of Cancer, Digestive system clinical trials.
This study looks at how well the COVID-19 vaccine works in people with liver cancer who are being treated with immunotherapy drugs. It aims to understand if the vaccine is effective and safe for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have liver cancer (hepatocellular carcinoma).
- You are currently being treated with an immunotherapy drug (like atezolizumab, durvalumab, nivolumab, or pembrolizumab), alone or with other medicines.
- Your full medical records need to be available for the study.
- You must have had at least one imaging scan (like a CT or MRI) to check how your cancer is responding to treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
This trial is checking how the immune system works in people with primary liver cancer, looking at ways to prevent infections and manage the tumor. It is an observational study—meaning no new treatments are given—so it helps doctors learn more without adding extra medications.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.